Research on the Nature, Diagnosis, and Treatment of Obesity and Diabetes

Obesity Clinical Trial

Official title:

FOXA2 Expression in Adipose Tissue of Human Subjects With Obesity/Insulin-Resistance

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00229268
• Other study ID #: MST-0513
• Status: Completed
• Phase: N/A
• First received: September 27, 2005
• Last updated: May 31, 2012
• Start date: September 2005
• Est. completion date: April 2010

Study information

• Verified date: May 2012
• Source: Rockefeller University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to determine whether the level of FOXA2 expression in fat tissue is a biomarker of insulin resistance. To test this hypothesis, we will perform euglycemic-hyperinsulinemic clamps in normal and obese human subjects to calculate insulin sensitivity, and see if insulin sensitivity correlates with the FOXA2 expression in subcutaneous fat.

Description:

The investigators at Rockefeller University Hospital are engaged in research on the nature, diagnosis and treatment of obesity and diabetes. The investigators are trying to find out why insulin, a blood sugar lowering hormone that is released by the pancreas following a meal, does not work effectively in individuals with obesity or type 2 diabetes. The investigators have recently discovered a protein in fat cells of obese mice that helps fat cells to take up and break down sugar from the blood. This protein (called FOXA2) also prevents the generation of more fat cells. FOXA2 is only present in obese mice, but absent from fat stores of lean animals. Insulin can stimulate the production of FOXA2 in fat cells. Furthermore, the levels of FOXA2 protein correlate with the degree of blood insulin levels. In this study, we are would like to determine whether FOXA2 is also produced in fat cells of humans, and if its level correlates with the degree of obesity and insulin resistance.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 14
• Est. completion date: April 2010
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 21 Years to 45 Years

Eligibility

Inclusion Criteria:

1. Healthy individuals

2. Age 21-45 years old

3. BMI: either < 25, or 30-35, or > 40

4. All patients must be willing and able to sign an informed consent form -

Exclusion Criteria:

1. Chronic illnesses other the than mild forms of illnesses related to obesity, such as hypertension, hyperlipidemia, and others, that do not require medical treatment

2. Diabetes mellitus previously diagnosed as per subject report or an abnormal 2 hour OGTT at screening

3. Chronic drug treatment for any medical condition

4. Active weight reduction of more than 7 pounds in the last 3 months

5. History of bleeding or blood clotting disorders

6. Subjects with hemoglobin <8.5 gm/dl

7. Changes in smoking habits for the last 6 months

8. Current pregnancy or current breast-feeding in women

9. Allergic reaction to local anesthetics

10. History of anaphylaxis or anaphylactic-like reactions

11. Tendency to form scars (keloids) easily

12. Irregular menses

13. HIV and hepatitis B or C positive subjects -

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Insulin Resistance
• Obesity

Locations

Country	Name	City	State
United States	Rockefeller University Hospital	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Rockefeller University

Country where clinical trial is conducted

United States,